Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

The Life Sciences Industry Report: Trends & Predictions 2025 is built for those who are serious about growth, innovation, and ...

Qu – which, according to Parsa, is the fruit of a collaboration between a global team of experienced AI scientists, ...

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after ...

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage ...

The pharma industry's challenge to Medicare drug price negotiation powers continues to rumble on, with three drugmakers asking a US appeals court to revive their lawsuits. Lawyers for AstraZeneca ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

An evaluation of digital health technologies for hypertension by the Peterson Health Technology Institute (PHTI) finds some provide a clinical benefit, while others are lacking. On the plus side ...